logo
Should beginners still invest in gold? 3 things to consider now

Should beginners still invest in gold? 3 things to consider now

CBS News2 days ago
If you're a young investor ready to put money into a variety of asset classes, you may be familiar with a few traditional ones. Stocks, bonds and real estate all offer investors, especially beginners, relatively simple ways to grow their money over time. But in today's unusual economic climate, in which inflation is rising again but stock market performance is currently strong, these beginner investors may be less confident in their investment options. For some of these investors, a gold investment could be attractive.
An alternative asset better known as a hedge against inflation and portfolio diversifier, gold can still be a valuable alternative for beginner investors, even if it's conventionally thought of as an asset better suited for veteran and older investors. That said, there are some considerations beginners should account for before jumping into the gold market right now. Below, we'll break down three things to consider before adding a layer of gold to your portfolio.
Learn more about how gold can protect your money against inflation here.
Here are three items that prospective beginner gold investors should consider now, before buying in:
Gold is less of an income-producer in the way stocks and bonds are and more of an income protector. So, if you're younger and have not built up much in the way of retirement savings or discretionary income savings, diverting too much of your money into gold may not be advantageous. You'll need to think of your short-term goals, then, to decide if gold makes sense for you and, if it does, how much to invest in the yellow metal.
That said, with a longer investment horizon than other investors, beginners may see more material benefits over time than older investors with less time to play the market. So, consider short-term goals versus what can be accomplished long-term to see where you fall on the gold investing spectrum.
Learn how gold can help you meet your investment goals now.
Gold prices change throughout the day, meaning that beginners will need to pay close attention to market conditions if they want to invest in gold below the current price. Overall, however, the price volatility of the precious metal will need to be closely considered to determine how it fits into your overall investing plan. The price of gold has surpassed numerous price records since the start of 2024, with no significant signs of slowing.
So, waiting for a cheaper entry price point isn't likely a strategy worth pursuing. At the same time, at close to $3,400 per ounce currently, gold may be cost-prohibitive for beginner investors just getting started. Understand the recent price dynamics and predictions about future price changes, then, to better determine where gold can (or can't) fit into your overall portfolio.
It's always important to have a diversified portfolio, as many would attest in recent years when inflation and higher interest rates damaged the investments of many. Gold can reliably fill this role as its value tends to stay steady and even rise during inflationary periods.
This is partially why gold investing hit its highest point in more than a decade in 2023 as investors scrambled to diversify their portfolios. But how much of a diversifier you need, especially as a beginner or younger investor, will vary on a case-by-case basis. Consider speaking with a financial advisor, then, or a top gold investing company that can answer your questions and better help you build a personalized gold investing plan.
A gold investment has timeless benefits, regardless of where you stand on the investing spectrum. And, for beginners, gold can play a small but important role in a diversified portfolio, even in today's economic landscape. By closely evaluating their short-term goals, understanding the current price volatility in the gold climate and weighing their current needs for a portfolio diversification tool, these investors can improve their chances of gold success, both at this early stage of their investment timeline and, hopefully, well into the future.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Gold Notches Small Gain as US Inflation Data Aids Rate-Cut Bets
Gold Notches Small Gain as US Inflation Data Aids Rate-Cut Bets

Yahoo

time12 minutes ago

  • Yahoo

Gold Notches Small Gain as US Inflation Data Aids Rate-Cut Bets

(Bloomberg) -- Gold extended a modest gain, following a US inflation reading that was in line with expectations and reinforced wagers on the Federal Reserve cutting interest rates next month. Bullion edged up after closing 0.2% higher in the previous session, after underlying US inflation accelerated to the strongest since the start of the year — though a tepid rise in goods prices eased concerns about tariff-driven pressures. Sunseeking Germans Face Swiss Backlash Over Alpine Holiday Congestion To Head Off Severe Storm Surges, Nova Scotia Invests in 'Living Shorelines' New York Warns of $34 Billion Budget Hole, Biggest Since 2009 Crisis Five Years After Black Lives Matter, Brussels' Colonial Statues Remain For Homeless Cyclists, Bikes Bring an Escape From the Streets The data boosted speculation that the Fed will reduce borrowing costs next month, especially given a softening labor market. Gold, which pays no interest, typically benefits in a lower rate environment. Traders are still on the lookout for clarification on whether gold bar imports would be subject to tariffs. The US Customs and Border Protection agency stunned the market last week by saying they would be subject to duties, which prompted a spike in the premium for gold futures in New York over the spot price in London. On Monday, Trump said there would not be a levy but didn't elaborate. Futures and spot prices continued to converge after Trump's latest comments. The December contract on New York's Comex held near $3,400 an ounce on Wednesday, while spot gold traded near $3,355 an ounce. Gold has climbed about 28% this year, with the bulk of those gains in the first four months. It has been supported by heightened geopolitical and trade tensions that have spurred haven demand, along with strong central bank purchases. Spot gold edged 0.4% higher to $3,360.70 an ounce at 8:25 a.m. in London. The Bloomberg Dollar Spot Index was down 0.1%, after posting a 0.4% loss on Tuesday. Silver climbed as much as 1.3%, while platinum and palladium also gained. Bessent on Tariffs, Deficits and Embracing Trump's Economic Plan Why It's Actually a Good Time to Buy a House, According to a Zillow Economist Dubai's Housing Boom Is Stoking Fears of Another Crash The Social Media Trend Machine Is Spitting Out Weirder and Weirder Results A $340 Million New York Office Makeover Is Converting Boardrooms to Bedrooms ©2025 Bloomberg L.P. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Martinrea International Inc (MRETF) Q2 2025 Earnings Call Highlights: Strong Financial ...
Martinrea International Inc (MRETF) Q2 2025 Earnings Call Highlights: Strong Financial ...

Yahoo

time12 minutes ago

  • Yahoo

Martinrea International Inc (MRETF) Q2 2025 Earnings Call Highlights: Strong Financial ...

Adjusted Operating Income: $86.1 million, up from $81.6 million in Q2 of last year. Adjusted Operating Income Margin: 6.8%, up 50 basis points year over year. Free Cash Flow (before IFRS 16 lease payments): $72 million, up from $51.7 million in Q2 of last year. Free Cash Flow (including IFRS 16 lease payments): $57.9 million. Adjusted Net Earnings Per Share: $0.66, up from $0.58 in Q2 of 2024. Net Debt: Decreased by approximately $73 million to $792 million. Net Debt to Adjusted EBITDA Ratio: 1.5x, down from 1.64x in Q1. 2025 Outlook: Total sales of $4.8 billion to $5.1 billion, adjusted operating income margin of 5.3% to 5.8%, and free cash flow of $125 million to $175 million. New Business Awards: $40 million in annualized sales, with $18 million from Stellantis and $22 million from Volkswagen and Volvo trucks. Warning! GuruFocus has detected 3 Warning Signs with MRETF. Release Date: August 12, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Martinrea International Inc (MRETF) reported a strong second quarter with stable production levels, good profits, operating margin, and free cash flow. The company achieved notable margin improvements compared to the first quarter, driven by operational enhancements and negotiated commercial recoveries. Martinrea's machine learning initiatives, including adaptive welding software and AI vision systems, have resulted in significant cost savings and efficiency improvements. The company has been awarded new business worth $40 million in annualized sales, indicating a healthy pipeline and growth potential. Martinrea is on track to meet its 2025 outlook, with strong free cash flow generation and a solid balance sheet, maintaining a net debt to adjusted EBITDA ratio of 1.5x. Negative Points The company faces some tariff exposure, particularly from Tier 2 suppliers and parts affected by steel and aluminum tariffs, although it is considered manageable. Production sales are expected to be lower in the second half of the year due to typical seasonal patterns, which may impact margins. There are uncertainties regarding the impact of tariffs and the strength of the US economy in the second half of the year. Commercial recoveries in Europe have been limited, and the timing of these negotiations is somewhat out of the company's control. The company is maintaining a minimal footprint in the Rest of the World segment, which can result in profit swings due to changes in volumes and commercial settlements. Q & A Highlights Q: Can you provide additional commentary on the back-half margin guide, considering the strong margins despite lower sales in North America? A: Peter Cirulis, CFO: The second half will be impacted by seasonal adjustments, with production levels expected to be lower. There were some one-time favorable effects in Q2 that won't repeat in the second half, including contractual price reductions with certain customers. However, we expect a strong performance in the third quarter, with some opacity in the fourth. Q: Are there specific facilities in North America driving productivity and efficiency improvements? A: Pat D'Eramo, CEO: We don't focus on specific facilities, but our lean manufacturing journey is showing results across the board. Some plants are particularly advanced, and our machine learning initiatives are contributing to improvements. Overall, our operations are performing well globally. Q: Will there be any commercial recoveries in Europe in the second half of the year? A: Peter Cirulis, CFO: Commercial recoveries are somewhat unpredictable in terms of timing, but we expect some issues to be resolved in the second half. Over time, we anticipate fewer recoveries as the industry normalizes. Q: How do you view the impact of tariffs on your North American operations, given the strong margins? A: Peter Cirulis, CFO: There was a tariff headwind in Q2, but it was manageable. We expect to recover a large extent of this impact by year-end. The strong margins are also supported by our operational improvements and commercial activities. Q: With discussions on production reshoring, what are the implications for your facilities in Canada and Mexico? A: Pat D'Eramo, CEO: It depends on the source of the work. If it's new work from Asian or European OEMs, we will place it where it makes logistical sense. For work moving within North America, our existing footprint is well-positioned to handle it. This could create opportunities for our Canadian facilities. Q: What is your outlook on CapEx, given the recent trends? A: Peter Cirulis, CFO: We are comfortable with a $300 million CapEx target, but it could vary depending on the cadence of our launches and program extensions. We aim to align CapEx with depreciation. Q: How do you view the valuation of Martinrea compared to US peers, and would you consider re-domiciling to the US? A: Robert Wildeboer, Executive Chairman: We acknowledge the valuation discount and have bought back shares. Re-domiciling has tax implications, but we are aware of the value and will consider different strategies. We believe our shares are undervalued, which is why we've been buying them back. Q: What are your thoughts on the investment in NanoXplore and the potential of graphene? A: Robert Wildeboer, Executive Chairman: We believe graphene has a promising future and have used it in leading-edge products. While we don't use a large quantity, it contributes to our profitability. We are optimistic about its potential applications and the recognition of its value. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data

Taysha Gene Therapies Inc (TSHA) Q2 2025 Earnings Call Highlights: Regulatory Milestones and ...
Taysha Gene Therapies Inc (TSHA) Q2 2025 Earnings Call Highlights: Regulatory Milestones and ...

Yahoo

time12 minutes ago

  • Yahoo

Taysha Gene Therapies Inc (TSHA) Q2 2025 Earnings Call Highlights: Regulatory Milestones and ...

Research and Development Expenses: $2.1 million for Q2 2025, compared to $15.1 million for Q2 2024. General and Administrative Expenses: $8.6 million for Q2 2025, compared to $7.3 million for Q2 2024. Net Loss: $26.9 million or $0.9 per share for Q2 2025, compared to $20.9 million or $0.9 per share for Q2 2024. Cash and Cash Equivalents: $312.8 million as of June 30, 2025. Follow-on Financing Proceeds: $230 million from May 2025, including full exercise of underwriters' option. Refinanced Loan: New debt facility of $50 million upfront with Trinity Capital, deferring principal payments by over 2.5 years. Warning! GuruFocus has detected 4 Warning Signs with TSHA. Release Date: August 12, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Taysha Gene Therapies Inc (NASDAQ:TSHA) has obtained alignment with the FDA and Health Canada to proceed with initiating their REVEAL pivotal trial for TSHA-102, indicating strong regulatory progress. The company reported positive clinical data supporting the therapeutic potential of TSHA-102, with all 10 patients in Part A of the REVEAL trials gaining or regaining developmental milestones. TSHA-102 is designed to target the genetic root cause of Rett syndrome, leveraging a clinically proven AAV9 vector and a minimally invasive lumbar intrathecal injection method. The company completed a public follow-on offering, resulting in total gross proceeds of $230 million, extending their cash runway into 2028. Taysha Gene Therapies Inc (NASDAQ:TSHA) has a defined path to registration for TSHA-102, with a pivotal trial underway and a strengthened balance sheet. Negative Points The company reported a net loss of $26.9 million for the three months ended June 30, 2025, compared to a net loss of $20.9 million for the same period in 2024. General and administrative expenses increased to $8.6 million for the three months ended June 30, 2025, primarily due to higher legal and professional fees. There are no currently approved therapies that treat the underlying genetic root cause of Rett syndrome, highlighting the urgency and challenge of developing effective treatments. The company faces risks and uncertainties that may cause actual results to differ materially from forward-looking statements, as noted in their SEC filings. The pivotal trial design relies on a novel regulatory pathway, which may present challenges in terms of regulatory approval and market acceptance. Q & A Highlights Q: Given there was a 100% response rate for the pivotal trial primary endpoint in Part A of the study, is this the bar for Part B in your view? A: Sean Nolan, CEO: The results from Part A are compelling, but maintaining a 100% response rate is challenging. The statistical plan for Part B uses a null hypothesis of 6.7%, meaning only 1 out of 15 patients might spontaneously gain or regain a milestone. The statistical bar is relatively low, around 33%, and the numbers from Part A are significantly above this threshold. Q: Are there certain time points where all milestones are occurring, or are additional ones seen over time? Have the benefits of the gene therapy plateaued? A: Elsa Rosignol, Director of Integrated Rett Syndrome Clinic: We see increasing improvements over time, not just at one visit. Gains occur at most follow-up visits, and some critical gains in daily functioning are not captured in the developmental milestone assessment but are still significant improvements. Q: How does your gene therapy differentiate from competitors, particularly regarding study design and primary endpoints? A: Sean Nolan, CEO: Our approach is unique, focusing on clinically meaningful and objective gains in activities of daily living. We've worked with regulators to establish a new paradigm in assessing clinical efficacy through milestone gains. This approach is supported by KOLs, advocacy groups, and regulators, emphasizing the therapy's impact on quality of life. Q: Would you expect any pushback on using your interim readout to support BLA filing, given your competitor's feedback on a 6-month endpoint? A: Sean Nolan, CEO: Our interim analysis approach is data-driven, based on robust support from Part A data. We've discussed this with the FDA, focusing on further refinements of the analysis rather than overturning key trial design elements. We feel confident about our position. Q: Can you characterize any changes from Part A CMC material batch to Part B, specifically regarding full to empty capsid ratio? How many patients can you supply with commercial-scale material? A: Sean Nolan, CEO: We've aligned with the FDA that Part A and pivotal material are analytically comparable. We've made the product for the pivotal trial with the commercial process at scale. Our cash runway into 2028 allows us to build commercial inventory as needed, ensuring we're well-positioned on the CMC side. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store